


AMENDMENTS

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A pharmaceutical compound according to Formula I,



FORMULA I


wherein R1, R2, R3 and R4 are selected from the group consisting of a straight or branched chain alkyl group having 1 to 6 carbons substitutes with one or more Ra groups, a benzyl group, a phenyl group which is substituted with one or two Rb groups, and a benzyl group which is substituted with one or two Rb groups;

wherein R1, R2, R3 and R4 are selected from the group consisting of halogen, -NO₂, -OCH₃, -OCH₂CH₃, -CH(CH₃)₂, [-(CH₂)_nOH], -(CH₂)OH, -(CH₂)₂OH, -(CH₂)₃OH, -(CH₂)₄OH, [-(CH₂)_nNH₂], -(CH₂)NH₂, -(CH₂)₂NH₂, -(CH₂)₃NH₂, -(CH₂)₄NH₂, -(CH₂)₅NH₂, -CH₂CH₂N(CH₃)₂, -CH₂CH₂NH(CH₂)₂OH, cyclopentane, 2,3-(CH₃)₂-cyclohexane, -S-Rc, -O-CO-Rd, -N-Re, -CO-Rf, -CONH-Rg; and

wherein Ra, Rb, Rc, Rd, Re, Rf, Rg are selected from the group consisting of a straight or branched chain alkyl group having 1 to 6 carbons, -NO₂, -OCH₃, -OCH₂CH₃, -CH(CH₃)₂, [-(CH₂)_nOH], -(CH₂)OH, -(CH₂)₂OH, -(CH₂)₃OH, -(CH₂)₄OH, [-(CH₂)_nNH₂], -(CH₂)NH₂, -(CH₂)₂NH₂, -(CH₂)₃NH₂, -(CH₂)₄NH₂, -(CH₂)₅NH₂, -CH₂CH₂N(CH₃)₂, -CH₂CH₂NH(CH₂)₂OH, cyclopentane, 2,3-(CH₃)₂-cyclohexane, -S-, -OCO-, -N-, -CO-, -CONH-.


2. (Original) The compound according to claim 1, wherein R1, R2, R3 and R4 represent a substituted phenyl, benzyl, ethylphenyl, cyclopentane, and 2,3-(CH₃)₂-cyclohexane groups selected from the group consisting of 2-CH₃C₆H₄, 3-CH₃C₆H₄, 4-CH₃C₆H₄, 2-OHC₆H₄, 3-OHC₆H₄, 4-OHC₆H₄, 2-ClC₆H₄, 3-ClC₆H₄, 4-ClC₆H₄, 2-NO₂C₆H₄, 3-NO₂C₆H₄, 4-NO₂C₆H₄, 2-NH₂C₆H₄, 3-NH₂C₆H₄, 4-NH₂C₆H₄, and 2,4-Cl₂C₆H₃.
3. (Original) The compound according to claim 1, wherein R1, R2, R3 and R4 represent a substituted alkyl group selected from the group consisting of CH₂Br, CH₂Cl, CH₂OH, C(CH₃)₃, (CH₂)₂OH, (CH₂)₃OH, (CH₂)₄OH, CH₂NH₂, (CH₂)₂NH₂, (CH₂)₃NH₂, (CH₂)₄NH₂, (CH₂)₅NH₂, CH₂N(CH₃)₂, (CH₂)₂N(CH₃)₂, (CH₂)₂NH(CH₂)₂OH, (CH₂)₃NH(CH₂)₂OH, (CH₂)₂NHCH₂OH, (CH₂)₃NHCH₂OH, CH₂CH(CH₃)₂, CHCl₂, CH(CH₃)Cl, (CH₂)₂Cl, (CH₂)₃Cl, (CH₂)₃Br, (CH₂)₄Br, and (CH₂)₄Cl.
4. [Cancelled]
5. [Cancelled]
6. [Cancelled]
7. [Cancelled]
8. [Cancelled]
9. [Cancelled]

10. (Original) A compound having the chemical structure of Formula I,



wherein R1, R2, R3 and R4 represent cyclopentane, cyclohexane, $-C_6H_5$, $-CH_2C_6H_5$, or $-CH_2CH_2C_6H_5$, group having one, two or three substituents which is selected from the group of halogen, OH, CH_3 , OCH_3 , NH_2 , and NO_2 .

11. (Original) A compound having the chemical structure of Formula I,



wherein R1, R2, R3 and R4 represent $-S-$, $-O-CO-$, $-N-$, $-CO-$, and $-CONH-$, consisting of a straight or branched chain alkyl group having 1 to 6 carbons, and CH_2Br , CH_2Cl , CH_2OH , $C(CH_3)_3$, $(CH_2)_2OH$, $(CH_2)_3OH$, $(CH_2)_4OH$, CH_2NH_2 , $(CH_2)_2NH_2$, $(CH_2)_3NH_2$, $(CH_2)_4NH_2$, $(CH_2)_5NH_2$, $CH_2N(CH_3)_2$, $(CH_2)_2N(CH_3)_2$, $(CH_2)_2NH(CH_2)_2OH$, $(CH_2)_3NH(CH_2)_2OH$, $(CH_2)_2NHCH_2OH$, $(CH_2)_3NHCH_2OH$, $CH_2CH(CH_3)_2$, $CHCl_2$, $CH(CH_3)Cl$, $(CH_2)_2Cl$, $(CH_2)_3Cl$, $(CH_2)_3Br$, $(CH_2)_4Br$, and $(CH_2)_4Cl$.

12. (Cancelled)

13. (Original) A method for anti-cancer treatment, comprising administering a therapeutically effective amount of a pharmaceutical compounds according to claim 11 or a pharmaceutically acceptable salt of said compound and optionally a pharmaceutical carrier to a patient in need of such treatment.

14. (Original) A method for treating abnormal proliferation, comprising administering a therapeutically effective amount of a pharmaceutical compounds according to claim 11 or a pharmaceutically acceptable salt of said compound and optionally a pharmaceutical carrier to a patient in need of such treatment.
15. (Original) A method for enhancing an anti-oxidation affect, comprising administering a therapeutically effective amount of a pharmaceutical compounds according to claim 11 or a pharmaceutically acceptable salt of said compound and optionally a pharmaceutical carrier to a patient in need of such treatment.
16. (Original) A method for enhancing human telomerase activity, comprising administering a therapeutically effective amount of a pharmaceutical compounds according to claim 11 or a pharmaceutically acceptable salt of said compound and optionally a pharmaceutical carrier to a patient in need of such treatment.
17. (Original) A method for stem cell research, comprising administering a therapeutically effective amount of a pharmaceutical compounds according to claim 11 or a pharmaceutically acceptable salt of said compound and optionally a pharmaceutical carrier to a patient in need of such treatment.
18. (Original) A method for enhancing tissue engineering application, comprising administering a therapeutically effective amount of a pharmaceutical compounds according to claim 11 or a pharmaceutically acceptable salt of said compound and optionally a pharmaceutical carrier to a patient in need of such treatment.
19. [Cancelled]
20. [Cancelled]
21. [Cancelled]
22. [Cancelled]
23. [Cancelled]

24. [Cancelled]

25. [Cancelled]